The existence of a French laboratories network performing this test in clinical routine makes it possible to generalize UGT1A1 deficiency screening , so as to guarantee equal access to safe treatment and optimized irinorecan -based therapy for the many patients receiving irinotecan -based therapy in advanced colorectal cancer .